C.E.O. Anne Wojcicki grapples with the ethical questions that come with building a business off customers’ personal information.
The two leading coronavirus vaccines seemed to work well in elderly trial volunteers. “I just can’t understand why people are afraid,” one 95-year-old said.
Queasy Americans, fighting upset stomachs and worries about the pandemic, have stocked up on prescription and over-the-counter medications, making them scarce in some parts of the country.
Some coronavirus vaccines rely on a shark-based product, but that doesn’t mean you shouldn’t get immunized.
Big profits beckon for pharmaceutical companies, which are already using their work on vaccines to fight efforts in Washington to curb drug prices.
The arrangement brings the Trump administration’s investment in coronavirus vaccine projects to more than $8 billion. The head of the federal effort is a former GSK executive.
The French drugmaker is testing two types of vaccines in a bid to catch up to competitors.
Moncef Slaoui, a former pharmaceutical executive, is now overseeing the U.S. initiative to development coronavirus treatments and vaccines. His financial interests and corporate roles have come under scrutiny.
The chief operating officer will be an Army general who specializes in logistics.
Facing a global scramble for materials, British officials bought millions of unproven kits from China in a gamble that became an embarrassment.